MondegarAI
Velan Capital Investment Management LP

Q4 2024 · 13F-HR

Velan Capital Investment Management LPholdings as filed

Filed 2025-02-14 · accession 0001848809-25-000001

$115.9M
Reported value
45
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
471871202JSPRJASPER THERAPEUTICS INC$30.7M26.5%1,433,828CommonSOLE
74006W207PRAXPRAXIS PRECISION MEDICINES I$23.1M19.9%300,000CommonSOLE
427746102HRTXHERON THERAPEUTICS INC$10.7M9.22%6,986,744CommonSOLE
89157D105TRMLTOURMALINE BIO INC$8.6M7.42%423,795CommonSOLE
74365U107TARAPROTARA THERAPEUTICS INC$8.3M7.19%1,579,000CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$6.7M5.78%185,520CommonSOLE
76200L309RZLTREZOLUTE INC$3.9M3.38%800,000CommonSOLE
53635D202LQDALIQUIDIA CORPORATION$3.5M3.04%300,000CommonSOLE
488445206ZVRAZEVRA THERAPEUTICS INC$2.5M2.16%300,000CommonSOLE
45779A846NSPRINSPIREMD INC$2.4M2.05%904,029CommonSOLE
925050106VRNAVERONA PHARMA PLC$2.3M2.00%50,000CommonSOLE
76029N106REPLREPLIMUNE GROUP INC$2.2M1.90%181,367CommonSOLE
67080M103NRIXNURIX THERAPEUTICS INC$1.8M1.59%97,889CommonSOLE
46489V302CATXPERSPECTIVE THERAPEUTICS INC$1.6M1.38%500,000CommonSOLE
28617K101ELDNELEDON PHARMACEUTICALS INC$1.3M1.15%323,973CommonSOLE
50127T109KURAKURA ONCOLOGY INC$1.3M1.13%150,000CommonSOLE
19459J104COLLCOLLEGIUM PHARMACEUTICAL INC$821,8250.71%28,685CommonSOLE
05338F306AVTXAVALO THERAPEUTICS INC$817,0920.71%109,972CommonSOLE
21833P301CRBPCORBUS PHARMACEUTICALS HLDGS$669,0600.58%56,700CommonSOLE
88032L605TENXTENAX THERAPEUTICS INC$515,8310.45%83,333CommonSOLE
49721T507KPRXKIORA PHARMACEUTICALS INC$403,3360.35%122,223CommonSOLE
374163103GERNGERON CORP$173,4600.15%49,000CommonSOLE
Y95308105WVEWAVE LIFE SCIENCES LTD$160,8100.14%13,000CommonSOLE
75915K309RGLSREGULUS THERAPEUTICS INC$110,6000.10%70,000CommonSOLE
N71542109PRQRPROQR THRAPEUTICS N V$107,3250.09%40,500CommonSOLE
014442107ALECALECTOR INC$103,9500.09%55,000CommonSOLE
21077P108CNTXCONTEXT THERAPEUTICS INC$94,5000.08%90,000CommonSOLE
880881107430TERNS PHARMACEUTICALS INC$94,1800.08%17,000CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$76,6500.07%35,000CommonSOLE
29251M106ENTAENANTA PHARMACEUTICALS INC$74,7500.06%13,000CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$69,6600.06%18,000CommonSOLE
38341P102GOSSGOSSAMER BIO INC$67,8450.06%75,000CommonSOLE
00461U105ACRSACLARIS THERAPEUTICS INC$66,9600.06%27,000CommonSOLE
690469101OVIDOVID THERAPEUTICS INC$65,3590.06%70,000CommonSOLE
35104E100FDMT4D MOLECULAR THERAPEUTICS IN$55,7000.05%10,000CommonSOLE
869367102SUTRO BIOPHARMA INC$55,2000.05%30,000CommonSOLE
69353Y103PMVPPMV PHARMACEUTICALS INC$52,8500.05%35,000CommonSOLE
31572Q808FGENEURFIBROGEN INC$42,3600.04%80,000CommonSOLE
23284F105CTMXCYTOMX THERAPEUTICS INC$36,0500.03%35,000CommonSOLE
50107A104KRON1USDKRONOS BIO INC$33,2500.03%35,000CommonSOLE
48576U106KPTIEURKARYOPHARM THERAPEUTICS INC$27,0520.02%40,000CommonSOLE
097702104BOLT1EURBOLT BIOTHERAPEUTICS INC$26,7550.02%50,000CommonSOLE
28623U101ELEVATION ONCOLOGY INC$25,3170.02%45,000CommonSOLE
19188J409COCPCOCRYSTAL PHARMA INC$20,2000.02%10,000CommonSOLE
65343E108NXTCEURNEXTCURE INC$19,2750.02%25,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.